Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy Meeting Abstract
| Authors: | Weisel, K.; Mina, R.; Mylin, A.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M.; Shune, L.; Isufi, I.; Harrison, S.; Shah, U.; Schecter, J.; Lendvai, N.; Gries, K.; Katz, E.; Slaughter, A.; Lonardi, C.; Gilbert, J.; Li, Q.; Deraedt, W.; Filho, O. C.; Patel, N.; Karlin, L. |
| Abstract Title: | Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy |
| Meeting Title: | 21st Annual Meeting and Exposition of the International Myeloma Society |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 25-28 |
| Meeting Location: | Rio de Janeiro, Brazil |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S97 |
| End Page: | S98 |
| Language: | English |
| ACCESSION: | WOS:001325737900159 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)01999-2 |
| Notes: | Meeting Abstract: P-096 -- Source: Wos |
